iRegene’s NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy
iRegene Therapeutics announced that the U.S. FDA granted Special Exemption status to NouvNeu004 injection, approving...
iRegene Therapeutics
iRegene Therapeutics’ NouvNeu001 Receives FDA Fast Track Designation for Parkinson’s Therapy
China-based iRegene Therapeutics announced on August 15, 2025, that its self-developed injectable product, NouvNeu001, has...
iRegene Therapeutics Secures RMB 100 Million in Series B+ Financing to Advance iPSC Technology
Wuhan-based iRegene Therapeutics, a pioneer in AI-powered, chemically induced cell therapies, has reportedly raised close...
iRegene Therapeutics Secures Over USD 14 Million in Series B Financing to Advance Cell Therapies
iRegene Therapeutics, a Wuhan-based biotechnology company specializing in the development of AI-enhanced chemically induced cell...
iRegene’s Pioneering Cell Therapy NouvNeu001 Administered in Wuhan for Parkinson’s Disease
Wuhan-based cell therapy developer iRegene has reached a clinical milestone with the administration of its...
iRegene’s NouvSight001 Gains Orphan Drug Designation for Retinitis Pigmentosa Treatment
Wuhan-based cell therapy innovator iRegene has secured Orphan Drug Designation (ODD) from the U.S. FDA...